This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
3-MeO-PCE: Difference between revisions
>Jared |
>Graham m wiki ref formatting |
||
| Line 5: | Line 5: | ||
'''3-Methoxyeticyclidine''' (also known as '''Methoxieticyclidine''' and '''3-MeO-PCE''') is a novel [[Psychoactive class::dissociative]] substance of the [[Chemical class::arylcyclohexylamine]] class that produces [[dissociative]] and [[hallucinogenic]] effects when [[Routes of administration|administered]]. It is a structural analog of [[PCE]]. | '''3-Methoxyeticyclidine''' (also known as '''Methoxieticyclidine''' and '''3-MeO-PCE''') is a novel [[Psychoactive class::dissociative]] substance of the [[Chemical class::arylcyclohexylamine]] class that produces [[dissociative]] and [[hallucinogenic]] effects when [[Routes of administration|administered]]. It is a structural analog of [[PCE]]. | ||
3-MeO-PCE began to gain popularity in 2010 <ref>3-MeO-PCE - Explore - Google Trends | https://www.google.com/trends/explore?date=all&q=3-MeO-PCE</ref> and is sold on the online grey area [[research chemical]] market as a legal alternative to [[PCP]] or [[ketamine]].<ref>Syntheses and analytical characterizations of N-alkyl-arylcyclohexylamines. | 3-MeO-PCE began to gain popularity in 2010 <ref>3-MeO-PCE - Explore - Google Trends | https://www.google.com/trends/explore?date=all&q=3-MeO-PCE</ref> and is sold on the online grey area [[research chemical]] market as a legal alternative to [[PCP]] or [[ketamine]].<ref>{{cite journal | vauthors=((Wallach, J.)), ((Colestock, T.)), ((Cicali, B.)), ((Elliott, S. P.)), ((Kavanagh, P. V.)), ((Adejare, A.)), ((Dempster, N. M.)), ((Brandt, S. D.)) | journal=Drug Testing and Analysis | title=Syntheses and analytical characterizations of N-alkyl-arylcyclohexylamines | volume=8 | issue=8 | pages=801–815 | date= August 2016 | issn=1942-7611 | doi=10.1002/dta.1861}}</ref><ref>{{cite journal | vauthors=((De Paoli, G.)), ((Brandt, S. D.)), ((Wallach, J.)), ((Archer, R. P.)), ((Pounder, D. J.)) | journal=Journal of Analytical Toxicology | title=From the Street to the Laboratory: Analytical Profiles of Methoxetamine, 3-Methoxyeticyclidine and 3-Methoxyphencyclidine and their Determination in Three Biological Matrices | volume=37 | issue=5 | pages=277–283 | date=1 June 2013 | url=https://academic.oup.com/jat/article-lookup/doi/10.1093/jat/bkt023 | issn=0146-4760 | doi=10.1093/jat/bkt023}}</ref><ref>{{Citation | title=nsddb.eu | url=http://nsddb.eu/substance/296/}}</ref> | ||
Very little data exists about the pharmacological properties, metabolism, and toxicity of 3-MeO-PCE, and it has a very brief history of human usage. It is strongly recommended that one use harm reduction practices if using this substance. | Very little data exists about the pharmacological properties, metabolism, and toxicity of 3-MeO-PCE, and it has a very brief history of human usage. It is strongly recommended that one use harm reduction practices if using this substance. | ||
| Line 17: | Line 16: | ||
3-MeO-PCE acts principally as an [[NMDA receptor antagonist]]. NMDA receptors allow for electrical signals to pass between neurons in the brain and spinal column; for the signals to pass, the receptor must be open. Dissociatives close the NMDA receptors by blocking them. This disconnection of neurons leads to loss of feeling, difficulty moving, and eventually an almost identical equivalent of the famous “[http://en.wikipedia.org/wiki/K-hole k-hole].” | 3-MeO-PCE acts principally as an [[NMDA receptor antagonist]]. NMDA receptors allow for electrical signals to pass between neurons in the brain and spinal column; for the signals to pass, the receptor must be open. Dissociatives close the NMDA receptors by blocking them. This disconnection of neurons leads to loss of feeling, difficulty moving, and eventually an almost identical equivalent of the famous “[http://en.wikipedia.org/wiki/K-hole k-hole].” | ||
3-MeO-PCE has Ki values of 61 nM for the NMDA receptor, 743 nM for the dopamine transporter, 2097 nM for the histamine H2 receptor, 964 nM for the Alpha-2A adrenergic receptor, 115 nM for the serotonin transporter, 4519 nM for the σ1 receptor and 525 nM for the σ2 receptor. <ref> | 3-MeO-PCE has Ki values of 61 nM for the NMDA receptor, 743 nM for the dopamine transporter, 2097 nM for the histamine H2 receptor, 964 nM for the Alpha-2A adrenergic receptor, 115 nM for the serotonin transporter, 4519 nM for the σ1 receptor and 525 nM for the σ2 receptor. <ref>{{cite journal | vauthors=((Roth, B. L.)), ((Gibbons, S.)), ((Arunotayanun, W.)), ((Huang, X.-P.)), ((Setola, V.)), ((Treble, R.)), ((Iversen, L.)) | journal=PLOS ONE | title=Correction: The Ketamine Analogue Methoxetamine and 3- and 4-Methoxy Analogues of Phencyclidine Are High Affinity and Selective Ligands for the Glutamate NMDA Receptor | volume=13 | issue=3 | pages=e0194984 | date=22 March 2018 | url=https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0194984 | issn=1932-6203 | doi=10.1371/journal.pone.0194984}}</ref> | ||
==Subjective effects== | ==Subjective effects== | ||
| Line 181: | Line 180: | ||
*'''Germany:''' 3-MeO-PCE is controlled under the NpSG (''New Psychoactive Substances Act'')<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/anlage.html|title=Anlage NpSG|publisher=Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]|access-date=December 10, 2019|language=de}}</ref> as of July 18, 2019.<ref>{{cite web|url=http://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl119s1083.pdf|title=Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes|publisher=Bundesanzeiger Verlag|work=Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27|pages=1083-1094|publication-date=July 17, 2019|access-date=January 1, 2020|language=de}}</ref> Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/__4.html|title=§ 4 NpSG|publisher=Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]|access-date=December 10, 2019|language=de}}</ref> | *'''Germany:''' 3-MeO-PCE is controlled under the NpSG (''New Psychoactive Substances Act'')<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/anlage.html|title=Anlage NpSG|publisher=Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]|access-date=December 10, 2019|language=de}}</ref> as of July 18, 2019.<ref>{{cite web|url=http://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl119s1083.pdf|title=Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes|publisher=Bundesanzeiger Verlag|work=Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27|pages=1083-1094|publication-date=July 17, 2019|access-date=January 1, 2020|language=de}}</ref> Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/__4.html|title=§ 4 NpSG|publisher=Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]|access-date=December 10, 2019|language=de}}</ref> | ||
*'''Switzerland:''' 3-MeO-PCE is a controlled substance specifically named under Verzeichnis E.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref> | *'''Switzerland:''' 3-MeO-PCE is a controlled substance specifically named under Verzeichnis E.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref> | ||
*'''Turkey:''' 3-MeO-PCE is a classed as drug and is illegal to possess, produce, supply, or import.<ref name="Bakanlar Kurulu Kararı - Karar Sayısı : 2013/5742">https://resmigazete.gov.tr/eskiler/2014/01/20140125-3.htm</ref> <ref name="List of illegal substances for law"> https://resmigazete.gov.tr/eskiler/2014/01/20140125-3-1.pdf</ref> | *'''Turkey:''' 3-MeO-PCE is a classed as drug and is illegal to possess, produce, supply, or import.<ref name="Bakanlar Kurulu Kararı - Karar Sayısı : 2013/5742">{{Citation | title=Başbakanlık Mevzuatı Geliştirme ve Yayın Genel Müdürlüğü | url=https://resmigazete.gov.tr/eskiler/2014/01/20140125-3.htm}}</ref> <ref name="List of illegal substances for law"> https://resmigazete.gov.tr/eskiler/2014/01/20140125-3-1.pdf</ref> | ||
*'''United Kingdom''' - 3-MeO-PCE is a class B drug in the UK and is illegal to possess, produce, supply, or import. As an N-alkyl derivative of 1-phenylcyclohexylamine substituted in the phenyl ring with an alkoxy substituent, it is covered by the arylcyclohexylamine generic clause added to the Misuse of Drugs Act by S.I. 2013/239, which came into effect on the 26th February 2013.<ref>The Misuse of Drugs Act 1971 (Amendment) Order 2013 | *'''United Kingdom''' - 3-MeO-PCE is a class B drug in the UK and is illegal to possess, produce, supply, or import. As an N-alkyl derivative of 1-phenylcyclohexylamine substituted in the phenyl ring with an alkoxy substituent, it is covered by the arylcyclohexylamine generic clause added to the Misuse of Drugs Act by S.I. 2013/239, which came into effect on the 26th February 2013.<ref>{{Citation | title=The Misuse of Drugs Act 1971 (Amendment) Order 2013 | url=https://www.legislation.gov.uk/uksi/2013/239/introduction/made}}</ref> | ||
==See also== | ==See also== | ||